CONFIDENTIAL SAP Version: 3.0 Effective Date: 09DEC2020 Page 26 of 27 Flowchart Footnotes a - pre-dose, when applicable. Note: Review of results for hematology, chemistry and pregnancy test (when applicable) is required prior to dosing. b - Full phy sical ex amination at baseline; tar geted phy sical ex amination at other time pointsc - Ur inaly sis per for med at Scr eening, Day 1, ev er y 4 weeks and as clinically indicated.d - Coagulation tests: prothrombin time, APTT and INR – only performed at Screening, first On Study Follow-up, and as clinically indicated. e - See Section 6.5 for assessment of vital signs on drug admin days. Note: when durvalumab vital assessments do not precede the BI 1361849 dose, p re-dos e vital as s es s ments mus t be done for BI 1361849. f - See section 7.1.5 for details r egar ding collection of AEs for 90 day s after last study dr ug administr ation g - Biopsy Samples: 1. A fresh core pre-treatment biopsy (minimum 3 cores from lung tissue or 4 cores from another site) obtained within 60 days of study start will be requested prior to study entry; archival sample may be used if a pre-treatment fresh biopsy is not feasible. NOTE: Per Amendment 9.1, biopsies should not be taken from a target lesion unless that is the only suitable lesion, in which case it should be of reasonable size (refer to Section 4.3.1.1). 2. If a fresh core pre-treatment biopsy was obtained, an on-treatment biopsy will be collected 1 week after the 3rd or 5th BI 1361849 treatment, if feasible; this on-treatment biopsy should only be collected if a pre-treatment fresh biopsy was obtained (so that paired biopsies may be examined). 3. Optional post-treatment core biopsies (minimum 3 cores from lung or 4 cores from another site) will be obtained at the time of tumor progression o r at the completion of tr eatment fr om subjects who consent to this pr ocedur e, and if clinically feasible. See Section 4.3.1.1 for details 4. If possible and as deter mined by Inv estigator , a minimum of 8 subjects in each ar m will hav e fr esh tissue sampling fr om which fine needle aspir ation (FNA) can be also obtained for immune profiling h - Standar d of C ar e pr ocedur es may be used for eligibility assessments pr ov ided they meet the cr iter ia specified in either the inclusion cr iter ia or flowchar t i - See Section 3.3 for instructions for blood draws for PBMC collection. Note: PBMC collection is discontinued per Amendment 9.1. J - Sampling at 7(±2) day s after pr eceding v accine administr ation. If v accine administr ation time points ar e delay ed, the P BM C & biological specimen collection time points should also be delay ed to maintain the 5-9 day time fr ame after pr eceding v accination. If the v accination is omitted, blood sampling should occur after the next subsequent vaccine administration. Sample for WBC (hematology ) must be av ailable for the day of the blood samples for immunomonitor ing. Note: Sample collection for PaxGene, PBMC, and humoral response is discontinued per Amendment 9.1 (See Section 4.3.1.2) Visits 6, 14, and 28 are no longer required per Amendment 9.1. k - If treatment is discontinued after <14 weeks of treatment, samples for PBMC, PaxGene and humoral response should be collected within 5-9 days after the last pr eceding v accination or as close as possible to this time fr ame if the 5-9 day window is not feasible. Note: Sample collection for PaxGene, PBMC, and humoral response is discontinued per Amendment 9.1 (See Section 4.3.1.2) Sponsor: Ludwig Institute for Cancer Research. Protocol Number: LUD2014- 012-VAC. CONFIDENTIAL SAP Version: 3.0 Effective Date: 09DEC2020 Page 27 of 27 17.2 Appendix B : Drug Administrative Schedules per Cycle